Drugs / Hydroxytyrosol
Hydroxytyrosol
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06833866 | Dec 2024 → Jun 2026 overdue | colorectal cancer | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02068092 | Dec 2013 → Jul 2021 | breast cancer | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02842567 | Apr 2017 → May 2018 | fatty liver disease | Bambino Gesù Hospital and Research Institute | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydroxytyrosol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06833866 ↗ |
| Known as | Homoprotocatechuyl alcohol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950045 ↗ |
| Known as | HXT | “We recently reported that Hydroxytyrosol (HXT) and Vitamin E (VitE) may improve oxidative stress, insulin resistance, and steatosis in children with biopsy-proven NAFLD.” PMID 33060043 ↗ Oct 2020 |
| Modality | Small molecule | — CHEMBL1950045 ↗ |
| Route | Oral | “Participants will take hydroxytyrosol orally once daily for 1 year.” NCT02068092 ↗ |